Analyst Articles
Eupraxia Raises $41M to Treat Painful Knees
Investors inject cash into Eupraxia Pharmaceuticals during its IPO on the TSX. The funds will be used to support clinical trials of their leading knee osteoarthritis treatment. Eupraxia’s polymer technology promises to flatten the drug-dose curve, providing long-term pain relief (up to 6 months) with fewer side effects. [more]